Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Evaluating reference-based pricing: initial findings and prospects.

Narine L, Senathirajah M, Smith T.

CMAJ. 1999 Aug 10;161(3):286-8.

2.

Evaluating the impact of reference-based pricing.

Grootendorst P, Holbrook A.

CMAJ. 1999 Aug 10;161(3):273-4. No abstract available.

3.

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005979. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD005979.

PMID:
16625648
4.

Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.

Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR.

CMAJ. 2001 Oct 16;165(8):1011-9.

5.

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ.

Clin Pharmacol Ther. 2003 Oct;74(4):388-400.

PMID:
14534526
6.

Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.

Ioannides-Demos LL, Ibrahim JE, McNeil JJ.

Pharmacoeconomics. 2002;20(9):577-91. Review.

PMID:
12141886
8.

Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.

Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB.

Clin Ther. 2003 Jan;25(1):273-84.

PMID:
12637126
9.

Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM.

CMAJ. 2002 Mar 19;166(6):737-45.

10.

European healthcare policies for controlling drug expenditure.

Ess SM, Schneeweiss S, Szucs TD.

Pharmacoeconomics. 2003;21(2):89-103.

PMID:
12515571
11.

Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.

Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M.

Med Care. 2004 Jul;42(7):653-60.

PMID:
15213490
12.

The impact of reference-pricing systems in Europe: a literature review and case studies.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):729-37. doi: 10.1586/erp.11.70. Review.

PMID:
22098289
13.

Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.

Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR.

CMAJ. 2002 Jun 25;166(13):1655-62.

14.
15.

Reference-based pricing in British Columbia: implications for cardiologists--an analysis.

Boulet AP, Tessier G.

Can J Cardiol. 1997 Jan;13(1):46-51. Review.

PMID:
9039064
16.
17.

Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.

Morgan SG, Agnew JD, Barer ML.

Health Policy. 2004 Jun;68(3):299-307.

PMID:
15113641
18.

Pharmaceutical reference prices. How do they work in practice?

Dickson M, Redwood H.

Pharmacoeconomics. 1998 Nov;14(5):471-9.

PMID:
10344913
19.

Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.

Andersson K, Petzold MG, Sonesson C, Lönnroth K, Carlsten A.

Health Policy. 2006 Dec;79(2-3):231-43. Epub 2006 Feb 13.

PMID:
16473436
20.

The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.

Moreno-Torres I, Puig-Junoy J, Raya JM.

Eur J Health Econ. 2011 Dec;12(6):563-73. doi: 10.1007/s10198-010-0271-1. Epub 2010 Sep 1.

PMID:
20809092

Supplemental Content

Support Center